Inhibrx, Inc.
Index- P/E- EPS (ttm)-2.86 Insider Own31.57% Shs Outstand39.04M Perf Week-15.74%
Market Cap608.82M Forward P/E- EPS next Y-3.81 Insider Trans-0.93% Shs Float26.73M Perf Month-39.18%
Income-110.80M PEG- EPS next Q-0.94 Inst Own68.80% Short Float12.20% Perf Quarter28.77%
Sales7.00M P/S86.97 EPS this Y-6.60% Inst Trans7.74% Short Ratio7.48 Perf Half Y-24.84%
Book/sh-0.13 P/B- EPS next Y-10.70% ROA-69.90% Target Price46.17 Perf Year-53.84%
Cash/sh4.36 P/C3.45 EPS next 5Y- ROE-430.10% 52W Range7.67 - 47.90 Perf YTD-65.56%
Dividend- P/FCF- EPS past 5Y- ROI-62.30% 52W High-69.29% Beta-
Dividend %- Quick Ratio7.50 Sales past 5Y- Gross Margin- 52W Low91.79% ATR1.82
Employees106 Current Ratio7.50 Sales Q/Q-30.00% Oper. Margin- RSI (14)33.91 Volatility7.96% 9.19%
OptionableYes Debt/Eq- EPS Q/Q-76.50% Profit Margin- Rel Volume0.64 Prev Close15.04
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume436.16K Price14.71
Recom1.80 SMA20-26.34% SMA50-20.81% SMA200-35.84% Volume53,398 Change-2.19%
Mar-16-22Initiated SMBC Nikko Outperform $40
Sep-21-21Initiated JMP Securities Mkt Outperform $46
Apr-26-21Resumed Credit Suisse Outperform $44
Sep-14-20Initiated Evercore ISI Outperform $30
Sep-14-20Initiated Credit Suisse Outperform $26
Aug-15-22 04:05PM  
Aug-08-22 07:25PM  
Jun-30-22 09:00AM  
May-19-22 04:05PM  
May-16-22 12:32PM  
May-09-22 06:35PM  
May-05-22 05:15PM  
May-03-22 06:32AM  
Apr-25-22 09:00AM  
Apr-05-22 04:30PM  
Mar-24-22 04:05PM  
Mar-03-22 09:15AM  
Feb-28-22 04:05PM  
Feb-22-22 09:00AM  
Jan-05-22 07:46AM  
Jan-04-22 04:05PM  
Dec-20-21 08:50AM  
Dec-01-21 04:05PM  
Nov-25-21 09:08AM  
Nov-24-21 10:31AM  
Nov-23-21 10:00AM  
Nov-10-21 07:47AM  
Nov-09-21 06:45PM  
Nov-05-21 03:00PM  
Nov-03-21 08:00AM  
Nov-01-21 05:51PM  
Oct-28-21 08:30AM  
Oct-12-21 12:22PM  
Oct-11-21 04:05PM  
Sep-13-21 04:30PM  
Aug-12-21 01:37AM  
Aug-09-21 04:38PM  
Jun-22-21 06:49AM  
Jun-21-21 04:05PM  
May-17-21 04:05PM  
May-13-21 04:10PM  
Mar-14-21 03:21AM  
Mar-12-21 09:00AM  
Feb-01-21 05:42PM  
Jan-13-21 09:00AM  
Dec-10-20 06:24PM  
Nov-13-20 04:10PM  
Nov-11-20 04:05PM  
Nov-05-20 04:05PM  
Aug-25-20 12:17PM  
Aug-21-20 04:00PM  
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Eckelman Brendan P.Chief Scientific OfficerSep 06Sale14.9140,000596,2742,435,553Sep 07 04:57 PM
Eckelman Brendan P.Chief Scientific OfficerAug 03Sale18.4715,500286,2092,475,553Aug 04 04:33 PM
Eckelman Brendan P.Chief Scientific OfficerAug 02Sale17.7024,500433,6262,491,053Aug 04 04:33 PM
Eckelman Brendan P.Chief Scientific OfficerJul 07Sale17.1740,000686,8002,515,553Jul 08 04:03 PM
Eckelman Brendan P.Chief Scientific OfficerApr 05Sale25.0440010,0162,555,553Apr 07 04:11 PM